These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 32130732)

  • 1. Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow.
    Petrackova A; Minarik J; Sedlarikova L; Libigerova T; Hamplova A; Krhovska P; Balcarkova J; Pika T; Papajik T; Kriegova E
    Br J Haematol; 2020 May; 189(4):e122-e125. PubMed ID: 32130732
    [No Abstract]   [Full Text] [Related]  

  • 2. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
    Lionetti M; Barbieri M; Manzoni M; Fabris S; Bandini C; Todoerti K; Nozza F; Rossi D; Musto P; Baldini L; Neri A
    Oncotarget; 2016 Apr; 7(16):21353-61. PubMed ID: 26870891
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma.
    Coffey DG; Wu QV; Towlerton AMH; Ornelas S; Morales AJ; Xu Y; Green DJ; Warren EH
    Blood Cancer J; 2019 Sep; 9(10):77. PubMed ID: 31570697
    [No Abstract]   [Full Text] [Related]  

  • 4. p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma.
    Ollikainen H; Syrjänen S; Koskela K; Pelliniemi TT; Pulkki K
    Scand J Clin Lab Invest; 1997 Jul; 57(4):281-9. PubMed ID: 9249875
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
    Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N
    Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-ras and p53 gene mutations are very rare events in multiple myeloma.
    Yasuga Y; Hirosawa S; Yamamoto K; Tomiyama J; Nagata K; Aokia N
    Int J Hematol; 1995 Aug; 62(2):91-7. PubMed ID: 8590778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma.
    Hao Y; Khaykin D; Machado L; van den Akker T; Houldsworth J; Barlogie B; Hussein S; El Jamal SM; Petersen B; Teruya-Feldstein J
    Mod Pathol; 2020 Feb; 33(2):188-195. PubMed ID: 31375765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Rare Episode of Extensive Bone Marrow Necrosis in a Chemotherapy-naïve Patient with Multiple Myeloma Exhibiting
    Jeon K; Kim HJ; Kim M; Lee YK
    Ann Clin Lab Sci; 2020 Jan; 50(1):136-139. PubMed ID: 32161023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.
    Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R
    Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rare occurrence of P53 gene mutations in multiple myeloma.
    Preudhomme C; Facon T; Zandecki M; Vanrumbeke M; Laï JL; Nataf E; Loucheux-Lefebvre MH; Kerckaert JP; Fenaux P
    Br J Haematol; 1992 Jul; 81(3):440-3. PubMed ID: 1390218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up.
    Carlebach M; Amiel A; Gaber E; Radnay J; Manor Y; Fejgin M; Lishner M
    Cancer Genet Cytogenet; 2000 Feb; 117(1):57-60. PubMed ID: 10700868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Genomic Sequencing Reveals Novel
    Jung YY; Woo HY; Kim HS
    Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
    van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
    Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
    Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
    Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
    Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.
    Peterson JF; Rowsey RA; Marcou CA; Pearce KE; Williamson CM; Frederick LA; Greipp PT; Ketterling RP; Kumar S; Viswanatha DS; Polley MY; Fink JM; Reichard KK; Van Dyke DL; Baughn LB
    Blood Cancer J; 2019 Feb; 9(3):20. PubMed ID: 30783078
    [No Abstract]   [Full Text] [Related]  

  • 17. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
    Jiménez C; Jara-Acevedo M; Corchete LA; Castillo D; Ordóñez GR; Sarasquete ME; Puig N; Martínez-López J; Prieto-Conde MI; García-Álvarez M; Chillón MC; Balanzategui A; Alcoceba M; Oriol A; Rosiñol L; Palomera L; Teruel AI; Lahuerta JJ; Bladé J; Mateos MV; Orfão A; San Miguel JF; González M; Gutiérrez NC; García-Sanz R
    J Mol Diagn; 2017 Jan; 19(1):99-106. PubMed ID: 27863261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
    Rustad EH; Boyle EM
    Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Next-Generation Sequencing Revealed TP53 Mutations to Be Malignant Marker for Intraductal Papillary Mucinous Neoplasms That Could Be Detected Using Pancreatic Juice.
    Takano S; Fukasawa M; Kadokura M; Shindo H; Takahashi E; Hirose S; Maekawa S; Mochizuki K; Kawaida H; Itakura J; Katoh R; Fujii H; Sato T; Enomoto N
    Pancreas; 2017; 46(10):1281-1287. PubMed ID: 28930868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relevance of TP53 for CLL diagnostics.
    Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
    J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.